The National Cancer Institute (NCI) awarded a $601,091 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The Ohio State University. The grant funds research on identifying and pharmacologically inhibiting the inflammatory damage-associated molecular pattern (DAMP) S100A9 as a strategy to reduce paclitaxel-induced peripheral neuropathy (PIPN) in cancer patients without affecting the drug's antitumor efficacy. The research aims to characterize the mechanisms underlying S100A9-mediated PIPN, establish an optimal regimen to pharmacologically inhibit S100A9 and prevent PIPN, and evaluate the safety and efficacy of combining paclitaxel with an S100A9 inhibitor in experimental breast cancer and non-small cell lung cancer models. This research is expected to provide new insights into the etiology of PIPN and lay the groundwork for a novel targeted intervention to mitigate this debilitating side effect of a widely used chemotherapy drug.
Generated 3/18/25, 5:11 AM